PapersFlow Research Brief
Cardiovascular Conditions and Treatments
Research Guide
What is Cardiovascular Conditions and Treatments?
Cardiovascular conditions and treatments in this context refer to the diagnosis and management of patent ductus arteriosus (PDA) in preterm infants, including indomethacin prophylaxis, ibuprofen treatment, echocardiography assessment, and their associations with neonatal morbidity, bronchopulmonary dysplasia, congenital heart disease, and cardiomyopathy.
This field encompasses 23,284 papers on PDA in preterm infants, focusing on indomethacin prophylaxis and ibuprofen treatment to promote ductal closure. Echocardiography serves as a key tool for assessing PDA and its links to outcomes like bronchopulmonary dysplasia and neonatal morbidity. Studies also examine PDA's relationship with congenital heart disease and cardiomyopathy.
Topic Hierarchy
Research Sub-Topics
Indomethacin Prophylaxis for Patent Ductus Arteriosus
This sub-topic evaluates early indomethacin administration to prevent PDA in preterm infants, assessing dosing regimens, efficacy via echocardiography, and short-term outcomes like intraventricular hemorrhage. Researchers conduct RCTs comparing prophylactic versus targeted approaches.
Ibuprofen Treatment of Patent Ductus Arteriosus
Studies compare oral and IV ibuprofen to indomethacin for PDA closure in neonates, monitoring ductal patency, renal function, and gastrointestinal side effects through serial ultrasounds. Meta-analyses guide treatment guidelines.
Echocardiographic Assessment of Patent Ductus Arteriosus
Researchers develop and validate echo criteria for PDA severity, including left atrial-to-aortic ratios and flow patterns in preterm infants. Work standardizes imaging protocols for predicting morbidity risks.
Patent Ductus Arteriosus and Bronchopulmonary Dysplasia
This area investigates hemodynamic links between persistent PDA and BPD development, analyzing ventilation needs and oxygen exposure post-closure. Longitudinal cohorts assess neurodevelopmental impacts.
Patent Ductus Arteriosus in Congenital Heart Disease
Studies explore PDA associations with cardiomyopathies and complex CHD, evaluating surgical ligation outcomes and genetic factors in neonates. Multimodal imaging tracks ductal evolution in syndromic cases.
Why It Matters
Patent ductus arteriosus treatments directly influence preterm infant outcomes by reducing neonatal morbidity and bronchopulmonary dysplasia through ductal closure via indomethacin prophylaxis or ibuprofen. "Task Force 1: the changing profile of congenital heart disease in adult life" by Warnes et al. (2001) outlines evolving profiles of congenital heart disease, including PDA-related conditions, affecting long-term adult care with 1414 citations. "Changing Mortality in Congenital Heart Disease" by Khairy et al. (2010) reports shifts in mortality rates, demonstrating improved survival post-intervention, with 877 citations. "Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease" by Feltes et al. (2011) provides guidelines for catheterization in PDA and related defects, guiding precise interventions with 815 citations.
Reading Guide
Where to Start
"Task Force 1: the changing profile of congenital heart disease in adult life" by Warnes et al. (2001) provides an accessible overview of congenital heart disease profiles, including PDA implications, as a foundational paper with 1414 citations.
Key Papers Explained
"Task Force 1: the changing profile of congenital heart disease in adult life" by Warnes et al. (2001) sets the stage for adult outcomes, which Khairy et al. (2010) in "Changing Mortality in Congenital Heart Disease" builds upon by quantifying mortality improvements. Feltes et al. (2011) in "Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease" offers intervention standards connecting to earlier diagnostic work like Thomas et al. (1993) in "Recommendations for Standards in Transthoracic Two‐Dimensional Echocardiography in the Dog and Cat." Hove et al. (2003) in "Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis" provides mechanistic insights foundational to these clinical advances.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on PDA's associations with neonatal morbidity and congenital heart disease using echocardiography. Emphasis remains on indomethacin prophylaxis and ibuprofen efficacy for ductal closure. No recent preprints available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Clinical Biochemistry of Domestic Animals | 1980 | Elsevier eBooks | 1.8K | ✓ |
| 2 | Task Force 1: the changing profile of congenital heart disease... | 2001 | Journal of the America... | 1.4K | ✕ |
| 3 | Tie2-Cre Transgenic Mice: A New Model for Endothelial Cell-Lin... | 2001 | Developmental Biology | 1.2K | ✕ |
| 4 | Recommendations for Standards in Transthoracic Two‐Dimensional... | 1993 | Journal of Veterinary ... | 1.0K | ✓ |
| 5 | Intracardiac fluid forces are an essential epigenetic factor f... | 2003 | Nature | 985 | ✕ |
| 6 | Holt-Oram syndrome is caused by mutations in TBX5, a member of... | 1997 | Nature Genetics | 925 | ✕ |
| 7 | Changing Mortality in Congenital Heart Disease | 2010 | Journal of the America... | 877 | ✕ |
| 8 | Small Animal Cardiovascular Medicine | 1998 | — | 830 | ✕ |
| 9 | Indications for Cardiac Catheterization and Intervention in Pe... | 2011 | Circulation | 815 | ✓ |
| 10 | Myocardial necrosis induced by temporary occlusion of a corona... | 1960 | PubMed | 777 | ✕ |
Frequently Asked Questions
What is the role of echocardiography in assessing PDA?
Echocardiography evaluates PDA size and ductal closure in preterm infants. "Recommendations for Standards in Transthoracic Two‐Dimensional Echocardiography in the Dog and Cat" by Thomas et al. (1993) establishes standardized imaging planes applicable to cardiovascular assessment, with 1004 citations. These standards support consistent diagnosis of PDA and related conditions.
How does indomethacin prophylaxis treat PDA?
Indomethacin prophylaxis promotes ductal closure in preterm infants to prevent neonatal morbidity. It targets PDA as a key factor in bronchopulmonary dysplasia. This approach reduces complications associated with persistent PDA.
What is the link between PDA and bronchopulmonary dysplasia?
Persistent PDA increases risk of bronchopulmonary dysplasia in preterm infants. Ductal closure via treatments like ibuprofen mitigates this morbidity. Studies confirm improved respiratory outcomes post-closure.
What are key indications for cardiac catheterization in pediatric heart disease?
"Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease" by Feltes et al. (2011) details criteria for interventions in conditions like PDA and congenital heart disease. These guidelines ensure targeted treatment to improve outcomes. The paper has 815 citations.
How has mortality changed in congenital heart disease?
"Changing Mortality in Congenital Heart Disease" by Khairy et al. (2010) documents declining mortality rates due to advances in diagnosis and treatment. This includes PDA management in neonates transitioning to adulthood. It has 877 citations.
Open Research Questions
- ? What are the long-term effects of indomethacin prophylaxis on neurodevelopmental outcomes in preterm infants with PDA?
- ? How does echocardiography precisely quantify hemodynamic impacts of PDA on bronchopulmonary dysplasia?
- ? What genetic factors link PDA to congenital heart disease and cardiomyopathy?
- ? Which biomarkers predict response to ibuprofen treatment for ductal closure?
- ? How do fluid forces in embryonic cardiogenesis influence postnatal PDA persistence?
Recent Trends
The field maintains 23,284 works with no specified 5-year growth rate.
Focus persists on PDA diagnosis and treatments in preterm infants, including echocardiography and pharmacological closure.
No recent preprints or news coverage reported.
Research Cardiovascular Conditions and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiovascular Conditions and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers